| Dr Ranjeet S Ajmani, CEO, PlasmaGen Bioscience |
Bio-Pharma India Summit ‘Today to Future 2020’ was recently held in Mumbai, which was attended by over 100 expert delegates. Dr Ranjeet S Ajmani, CEO, PlasmaGen Bioscience, who was the Chairperson for the event, gave the opening remarks with his presentation on blood plasma scenario in India and SAARC region. It was an event with thought provoking discussions and engaging content.
Leaders from biologics, biosimilars, diagnostics, devices and health management services and allied services took part in the conference.
| Panelists at the conference | |
Ajmani said, “India has made progress in certain areas of healthcare segment but somehow public health issue is still not addressed. This is one of the major concerns raised even by the Planning Commission of India. Providing safe blood/plasma products is an important concern, as it deals with transmission of HIV, Hepatitis B and C and many such diseases through these medicines. Unfortunately this issue has not been addressed well at various levels and it needs attention on an urgent basis, as it deals with patients of practically all categories. Some of the proteins fall in the category of essential medicine. It is also important for any country to have its national blood policy, blood security programme and self sufficiency for plasma protein therapy. We have major challenges in terms of availability of safe raw material, safety, affordability and out dated regulatory guidelines. The scene is almost similar in all the SAARC nations.”
| Charles M Y Lim, CEO Asia/ China, BIA Separations |
“India can create a sustainable model, which would help other developing economies to look into this aspect of healthcare system. This forum would help in raising/ sharing the concerns and probable solutions for developing a strong base for plasma protein therapy in India and SAARC region,” added Ajmani.
Charles M Y Lim, CEO Asia/ China, BIA Separations, spoke about downstream purification challenges, and strategies for increasing the capacity and quality in the production of new bio-therapeutics. Speakers from Reliance Life Sciences, Marken, ICON, Realisation, T-Tubes and Sanofi, took part on the first day of the event. Day two of the forum saw presentations from speakers involved in clinical research and vaccines.
The panel discussions witnessed interesting exchange of perspectives between panelists and audience.
EP News Bureau